pd 169316 has been researched along with Endotoxemia in 1 studies
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor
Endotoxemia: A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brooks, AC | 1 |
| Menzies-Gow, NJ | 1 |
| Wheeler-Jones, C | 1 |
| Bailey, SR | 1 |
| Cunningham, FM | 1 |
| Elliott, J | 1 |
1 other study available for pd 169316 and Endotoxemia
| Article | Year |
|---|---|
Endotoxin-induced activation of equine platelets: evidence for direct activation of p38 MAPK pathways and vasoactive mediator production.
Topics: Animals; Blood Platelets; Dose-Response Relationship, Drug; Endotoxemia; Endotoxins; Enzyme Inhibito | 2007 |